Skip to content
Back to TARS

Tarsus Pharmaceuticals, Inc.

Open-market purchases and sales reported on SEC Forms 4 and 5, with each filing and its footnotes.

Since Nov 18, 2025
Transactions
60
Purchases
0
Sales
60
Purchase value
$0.00
Sale value
$20.76M

Values are shares multiplied by reported price when both were supplied, each trade counted once however many filers reported it.

Bobak R. AzamianDirector · President/CEO and Board Chair
4Rule 10b5-1 plan disclosed
Filed Nov 17, 2026Period of report Nov 13, 20260001827672-26-000016
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleNov 13, 2026
Common StockF1F2F310,000$80.31$803.10K817,991IndirectBy the Bobak Azamian Living Trust established April 16, 2018
Filing footnotes · 3
  1. F1The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 9, 2025.
  2. F2The price reported in column 4 is a weighted average price. The shares were pooled and sold in multiple transactions at prices ranging from $80.00 to $80.56. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  3. F3The Reporting Person is the trustee of the Bobak Azamian Living Trust, established April 16, 2018 and has voting and dispositive power with respect to these shares.
Open on SEC EDGAR
William J PHD LinkDirector
4Rule 10b5-1 plan disclosed
Filed Sep 17, 2026Period of report Sep 15, 20260001228684-26-000010
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleSep 15, 2026
Common StockF2F311,675$78.33$914.50K95,312Direct
SaleSep 15, 2026
Common StockF2F4759$79.00$59.96K94,553Direct
SaleSep 15, 2026
Common StockF266$80.01$5.28K94,487Direct
Filing footnotes · 6
  1. F1The shares were issued pursuant to settlement of vested Restricted Stock Units ("RSUs"). Each RSU represents a contingent right to receive one share of the Company's common stock.
  2. F2The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 8, 2025.
  3. F3The price reported in column 4 is a weighted average price. The shares were pooled and sold in multiple transactions at prices ranging from $77.87 to $78.86. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  4. F4The price reported in column 4 is a weighted average price. The shares were pooled and sold in multiple transactions at prices ranging from $78.89 to $79.10. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  5. F5Each RSU represents a contingent right to receive one share of the Company's common stock.
  6. F6RSUs granted in connection with the Reporting Person's service as a non-employee director as of the Company's 2026 annual meeting of stockholders. The RSUs vest in equal installments on 9/15/2026, 12/15/2026, 3/15/2027 and 6/15/2027, subject to the non-employee director's continuous service.
Open on SEC EDGAR
Elizabeth Yeu LinChief Medical Officer
4Rule 10b5-1 plan disclosed
Filed Sep 9, 2026Period of report Sep 4, 20260001842190-26-000011
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleSep 4, 2026
Common StockF15,387$85.00$457.90K7,933Direct
SaleSep 4, 2026
Common StockF15,386$90.00$484.74K2,547Direct
SaleSep 4, 2026
Common StockF21,590$85.00$135.15K3,180IndirectBy Spouse's Roth IRA
SaleSep 4, 2026
Common StockF21,590$90.00$143.10K1,590IndirectBy Spouse's Roth IRA
Filing footnotes · 2
  1. F1The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 29, 2026.
  2. F2The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 1, 2026.
Open on SEC EDGAR
Bobak R. AzamianDirector · President/CEO and Board Chair
4Rule 10b5-1 plan disclosed
Filed Sep 9, 2026Period of report Sep 4, 20260001827672-26-000013
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleSep 4, 2026
Common StockF1F2F37,100$90.27$640.92K830,891IndirectBy the Bobak Azamian Living Trust established April 16, 2018
SaleSep 4, 2026
Common StockF1F4F32,900$91.27$264.68K827,991IndirectBy the Bobak Azamian Living Trust established April 16, 2018
Filing footnotes · 4
  1. F1The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 9, 2025.
  2. F2The price reported in column 4 is a weighted average price. The shares were pooled and sold in multiple transactions at prices ranging from $90.00 to $90.91. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  3. F3The Reporting Person is the trustee of the Bobak Azamian Living Trust, established April 16, 2018 and has voting and dispositive power with respect to these shares.
  4. F4The price reported in column 4 is a weighted average price. The shares were pooled and sold in multiple transactions at prices ranging from $91.06 to $91.45. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Open on SEC EDGAR
Seshadri NeervannanChief Operating Officer
4Rule 10b5-1 plan disclosed
Filed Sep 9, 2026Period of report Sep 4, 20260001827584-26-000013
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleSep 4, 2026
Common StockF1F24,564$85.00$387.94K78,532Direct
Filing footnotes · 3
  1. F1The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 13, 2025.
  2. F2Includes 305 shares acquired under the Issuer's Employee Stock Purchase Plan on June 30, 2026.
  3. F3This holding balance is related to the Reporting Person's daughter who shares the Reporting Person's household. The Reporting Person disclaims beneficial ownership of the securities held by his daughter, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of the securities for purposes of Section 16 or for any other purposes.
Open on SEC EDGAR
Elizabeth Yeu LinChief Medical Officer
4Rule 10b5-1 plan disclosed
Filed Sep 3, 2026Period of report Sep 1, 20260001842190-26-000009
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleSep 2, 2026
Common StockF15,387$80.00$430.96K13,320Direct
SaleSep 2, 2026
Common StockF21,590$80.00$127.20K4,770IndirectBy Spouse's Roth IRA
SaleSep 1, 2026
Common StockF14,601$73.86$339.83K18,707Direct
Filing footnotes · 2
  1. F1The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 29, 2026.
  2. F2The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 1, 2026.
Open on SEC EDGAR
Bobak R. AzamianDirector · President/CEO and Board Chair
4Rule 10b5-1 plan disclosed
Filed Sep 3, 2026Period of report Sep 2, 20260001827672-26-000011
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleSep 2, 2026
Common StockF1F2F310,000$80.06$800.60K837,991IndirectBy the Bobak Azamian Living Trust established April 16, 2018
Filing footnotes · 3
  1. F1The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 9, 2025.
  2. F2The price reported in column 4 is a weighted average price. The shares were pooled and sold in multiple transactions at prices ranging from $80.00 to $80.20. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  3. F3The Reporting Person is the trustee of the Bobak Azamian Living Trust, established April 16, 2018 and has voting and dispositive power with respect to these shares.
Open on SEC EDGAR
Bobak R. AzamianDirector · President/CEO and Board Chair
4Rule 10b5-1 plan disclosed
Filed Jun 22, 2026Period of report Jun 17, 20260001827672-26-000009
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleJun 17, 2026
Common StockF1F2F34,582$61.24$280.60K853,409IndirectBy the Bobak Azamian Living Trust established April 16, 2018
SaleJun 17, 2026
Common StockF1F4F35,418$61.81$334.89K847,991IndirectBy the Bobak Azamian Living Trust established April 16, 2018
Filing footnotes · 4
  1. F1The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 9, 2025.
  2. F2The price reported in column 4 is a weighted average price. The shares were pooled and sold in multiple transactions at prices ranging from $60.51 to $61.50. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  3. F3The Reporting Person is the trustee of the Bobak Azamian Living Trust, established April 16, 2018 and has voting and dispositive power with respect to these shares.
  4. F4The price reported in column 4 is a weighted average price. The shares were pooled and sold in multiple transactions at prices ranging from $61.52 to $62.13. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Open on SEC EDGAR
Jeffrey S FarrowSee Remarks
4
Filed Jun 17, 2026Period of report Jun 15, 20260001405253-26-000013
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleJun 16, 2026
Common StockF214,396$60.95$877.44K56,801Direct
Filing footnotes · 4
  1. F1The shares were issued pursuant to settlement of vested Restricted Stock Units ("RSUs"). Each RSU represents a contingent right to receive one share of the Company's common stock.
  2. F2The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.
  3. F3Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Company's common stock.
  4. F4RSUs granted on April 24, 2023, under the Tarsus Pharmaceuticals, Inc. 2020 Stock Plan. 25% of the RSUs will vest on June 15th of each of 2024, 2025, 2026 and 2027, subject to the Reporting Person's continuous service.
Open on SEC EDGAR
Katherine GoodrichDirector
4Rule 10b5-1 plan disclosed
Filed Jun 17, 2026Period of report Jun 15, 20260002044770-26-000006
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleJun 15, 2026
Common StockF12,954$62.08$183.38K2,233Direct
Filing footnotes · 1
  1. F1The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 27, 2026.
Open on SEC EDGAR
William J PHD LinkDirector
4Rule 10b5-1 plan disclosed
Filed Jun 17, 2026Period of report Jun 15, 20260001228684-26-000006
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleJun 15, 2026
Common StockF1F210,572$61.97$655.15K108,714Direct
SaleJun 15, 2026
Common StockF1F31,928$62.94$121.35K106,786Direct
Filing footnotes · 3
  1. F1The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 8, 2025.
  2. F2The price reported in column 4 is a weighted average price. The shares were pooled and sold in multiple transactions at prices ranging from $61.67 to $62.67. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  3. F3The price reported in column 4 is a weighted average price. The shares were pooled and sold in multiple transactions at prices ranging from $62.68 to $63.05. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Open on SEC EDGAR
Seshadri NeervannanChief Operating Officer
4Rule 10b5-1 plan disclosed
Filed Mar 24, 2026Period of report Mar 20, 20260001827584-26-000011
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleMar 20, 2026
Common StockF12,989$66.75$199.52K82,791Direct
Filing footnotes · 2
  1. F1The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 13, 2025.
  2. F2This holding balance is related to the Reporting Person's daughter who shares the Reporting Person's household. The Reporting Person disclaims beneficial ownership of the securities held by his daughter, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of the securities for purposes of Section 16 or for any other purposes.
Open on SEC EDGAR
Elizabeth Yeu LinChief Medical Officer
4
Filed Mar 19, 2026Period of report Mar 17, 20260001842190-26-000007
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleMar 19, 2026
Common StockF1390$67.00$26.13K23,308Direct
SaleMar 18, 2026
Common StockF1379$68.71$26.04K23,698Direct
SaleMar 17, 2026
Common StockF1375$69.42$26.03K24,077Direct
Filing footnotes · 1
  1. F1The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of Restricted Stock Units. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.
Open on SEC EDGAR
Bryan WahlGeneral Counsel
4
Filed Mar 19, 2026Period of report Mar 17, 20260001841401-26-000007
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleMar 19, 2026
Common StockF14,231$67.00$283.48K63,959Direct
SaleMar 18, 2026
Common StockF14,125$68.71$283.43K68,190Direct
SaleMar 17, 2026
Common StockF14,084$69.42$283.51K72,315Direct
Filing footnotes · 1
  1. F1The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of Restricted Stock Units. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.
Open on SEC EDGAR
Dianne C. WhitfieldChief Human Resources Officer
4
Filed Mar 19, 2026Period of report Mar 17, 20260001839516-26-000009
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleMar 19, 2026
Common StockF14,174$67.00$279.66K35,028Direct
SaleMar 18, 2026
Common StockF14,071$68.71$279.72K39,202Direct
SaleMar 17, 2026
Common StockF14,029$69.42$279.69K43,273Direct
Filing footnotes · 1
  1. F1The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of Restricted Stock Units. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.
Open on SEC EDGAR
Bobak R. AzamianDirector · President/CEO and Board Chair
4
Filed Mar 19, 2026Period of report Mar 17, 20260001827672-26-000007
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleMar 19, 2026
Common StockF111,964$67.00$801.59K33,421Direct
SaleMar 18, 2026
Common StockF111,667$68.71$801.64K45,385Direct
SaleMar 17, 2026
Common StockF110,972$69.42$761.68K57,052Direct
Filing footnotes · 2
  1. F1The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of Restricted Stock Units. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.
  2. F2The Reporting Person is the trustee of the Bobak Azamian Living Trust, established April 16, 2018 and has voting and dispositive power with respect to these shares.
Open on SEC EDGAR
Seshadri NeervannanChief Operating Officer
4
Filed Mar 19, 2026Period of report Mar 17, 20260001827584-26-000009
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleMar 19, 2026
Common StockF14,589$67.00$307.46K85,780Direct
SaleMar 18, 2026
Common StockF13,610$68.71$248.04K90,369Direct
SaleMar 17, 2026
Common StockF13,125$69.42$216.94K93,979Direct
Filing footnotes · 2
  1. F1The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of Restricted Stock Units. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.
  2. F2This holding balance is related to the Reporting Person's daughter who shares the Reporting Person's household. The Reporting Person disclaims beneficial ownership of the securities held by his daughter, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of the securities for purposes of Section 16 or for any other purposes.
Open on SEC EDGAR
Aziz MottiwalaChief Commercial Officer
4
Filed Mar 19, 2026Period of report Mar 17, 20260001788542-26-000007
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleMar 19, 2026
Common StockF14,440$67.00$297.48K61,480Direct
SaleMar 18, 2026
Common StockF14,330$68.71$297.51K65,920Direct
SaleMar 17, 2026
Common StockF14,286$69.42$297.53K70,250Direct
Filing footnotes · 1
  1. F1The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of Restricted Stock Units. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.
Open on SEC EDGAR
Jeffrey S FarrowSee Remarks
4
Filed Mar 19, 2026Period of report Mar 17, 20260001405253-26-000007
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleMar 19, 2026
Common StockF12,186$67.00$146.46K43,316Direct
SaleMar 18, 2026
Common StockF12,133$68.71$146.56K45,502Direct
SaleMar 17, 2026
Common StockF12,111$69.42$146.55K47,635Direct
Filing footnotes · 1
  1. F1The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of Restricted Stock Units. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.
Open on SEC EDGAR
William J PHD LinkDirector
4Rule 10b5-1 plan disclosed
Filed Mar 18, 2026Period of report Mar 16, 20260001228684-26-000002
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleMar 16, 2026
Common StockF1F23,629$68.09$247.10K125,203Direct
SaleMar 16, 2026
Common StockF1F38,378$69.03$578.33K116,825Direct
SaleMar 16, 2026
Common StockF1F4493$69.75$34.39K116,332Direct
Filing footnotes · 4
  1. F1The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 8, 2025.
  2. F2The price reported in column 4 is a weighted average price. The shares were pooled and sold in multiple transactions at prices ranging from $67.60 to $68.59. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  3. F3The price reported in column 4 is a weighted average price. The shares were pooled and sold in multiple transactions at prices ranging from $68.64 to $69.63. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  4. F4The price reported in column 4 is a weighted average price. The shares were pooled and sold in multiple transactions at prices ranging from $69.68 to $69.85. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Open on SEC EDGAR
Seshadri NeervannanChief Operating Officer
4Rule 10b5-1 plan disclosed
Filed Mar 5, 2026Period of report Mar 4, 20260001827584-26-000002
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleMar 4, 2026
Common StockF18,366$76.67$641.42K70,817Direct
Filing footnotes · 2
  1. F1The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 13, 2025.
  2. F2This holding balance is related to the Reporting Person's daughter who shares the Reporting Person's household. The Reporting Person disclaims beneficial ownership of the securities held by his daughter, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of the securities for purposes of Section 16 or for any other purposes.
Open on SEC EDGAR
Dianne C. WhitfieldChief Human Resources Officer
4Rule 10b5-1 plan disclosed
Filed Jan 6, 2026Period of report Jan 2, 20260001839516-26-000002
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleJan 2, 2026
Common StockF1F25,715$80.09$457.71K33,243Direct
SaleJan 2, 2026
Common StockF1F38,122$80.71$655.53K25,121Direct
SaleJan 2, 2026
Common StockF1F4835$81.90$68.39K24,286Direct
SaleJan 2, 2026
Common StockF1F5893$82.93$74.06K23,393Direct
Filing footnotes · 5
  1. F1The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 12, 2025.
  2. F2The price reported in column 4 is a weighted average price. The shares were pooled and sold in multiple transactions at prices ranging from $79.42 to $80.40. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  3. F3The price reported in column 4 is a weighted average price. The shares were pooled and sold in multiple transactions at prices ranging from $80.42 to $81.29. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  4. F4The price reported in column 4 is a weighted average price. The shares were pooled and sold in multiple transactions at prices ranging from $81.68 to $82.62. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  5. F5The price reported in column 4 is a weighted average price. The shares were pooled and sold in multiple transactions at prices ranging from $82.82 to $83.32. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Open on SEC EDGAR
Bobak R. AzamianDirector · President/CEO and Board Chair
4Rule 10b5-1 plan disclosed
Filed Dec 30, 2025Period of report Dec 24, 20250001827672-25-000007
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleDec 24, 2025
Common StockF1F2F35,443$82.41$448.56K858,548IndirectBy the Bobak Azamian Living Trust established April 16, 2018
SaleDec 24, 2025
Common StockF1F4F3557$83.54$46.53K857,991IndirectBy the Bobak Azamian Living Trust established April 16, 2018
Filing footnotes · 4
  1. F1The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 12, 2024.
  2. F2The price reported in column 4 is a weighted average price. The shares were pooled and sold in multiple transactions at prices ranging from $81.89 to $82.88. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  3. F3The Reporting Person is the trustee of the Bobak Azamian Living Trust, established April 16, 2018 and has voting and dispositive power with respect to these shares.
  4. F4The price reported in column 4 is a weighted average price. The shares were pooled and sold in multiple transactions at prices ranging from $83.14 to $84.04. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Open on SEC EDGAR
Dianne C. WhitfieldChief Human Resources Officer
4Rule 10b5-1 plan disclosed
Filed Dec 18, 2025Period of report Dec 16, 20250001839516-25-000003
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleDec 16, 2025
Common StockF17,397$80.10$592.50K38,958Direct
Filing footnotes · 1
  1. F1The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 12, 2025.
Open on SEC EDGAR
Elizabeth Yeu LinChief Medical Officer
4
Filed Dec 17, 2025Period of report Dec 15, 20250001842190-25-000003
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleDec 16, 2025
Common StockF32,078$79.50$165.20K21,941Direct
Filing footnotes · 5
  1. F1The shares were issued pursuant to settlement of vested Restricted Stock Units ("RSUs"). Each RSU represents a contingent right to receive one share of the Company's common stock.
  2. F2Since the date of the Reporting Person's last report, 9,506 shares previously owned by the Reporting Person's Spouse's Roth IRA were transferred to the Reporting Person's self-directed IRA and are now directly owned.
  3. F3The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.
  4. F4Each RSU represents a contingent right to receive one share of the Company's common stock.
  5. F5RSUs granted on November 4, 2024 in connection with the Reporting Person's appointment as Chief Medical Officer. 25% of the RSUs will vest on December 15th of each of 2025, 2026, 2027 and 2028, subject to the Reporting Person's continuous service.
Open on SEC EDGAR
William J PHD LinkDirector
4Rule 10b5-1 plan disclosed
Filed Dec 17, 2025Period of report Dec 15, 20250001228684-25-000005
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleDec 15, 2025
Common StockF1F25,046$80.80$407.72K136,286Direct
SaleDec 15, 2025
Common StockF1F36,306$81.75$515.52K129,980Direct
SaleDec 15, 2025
Common StockF1F41,148$82.39$94.58K128,832Direct
SaleDec 15, 2025
Common StockF5F6F75,680$80.71$458.43K4,766IndirectBy Link Family Enterprise, LP
SaleDec 15, 2025
Common StockF5F8F74,766$81.50$388.43K0IndirectBy Link Family Enterprise, LP
Filing footnotes · 8
  1. F1The sales were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 8, 2025.
  2. F2The price reported in column 4 is a weighted average price. The shares were pooled and sold in multiple transactions at prices ranging from $80.21 to $81.20. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  3. F3The price reported in column 4 is a weighted average price. The shares were pooled and sold in multiple transactions at prices ranging from $81.21 to $82.19. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  4. F4The price reported in column 4 is a weighted average price. The shares were pooled and sold in multiple transactions at prices ranging from $82.23 to $82.92. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  5. F5The sales were not effected by a sale pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.
  6. F6The price reported in column 4 is a weighted average price. The shares were pooled and sold in multiple transactions at prices ranging from $80.21 to $81.20. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  7. F7The Reporting Person may be deemed to beneficially own the shares indirectly by reason of the Reporting Person as the controlling member of Link Family Enterprise, LP.
  8. F8The price reported in column 4 is a weighted average price. The shares were pooled and sold in multiple transactions at prices ranging from $81.21 to $81.79. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Open on SEC EDGAR

P and S transaction codes only. Grants, gifts, option exercises, tax withholding, and Form 144 notices are not counted as purchases or sales. A row whose filed price fails a plausibility check, or that is not common stock, is listed but left out of the values; a trade reported by several filers is counted once.